logo
Plus   Neg
Share
Email

Roche To Present Data For Seven Medicines Across Breast Cancer Portfolio

Swiss drug maker Roche Group (RHHBY) announced Monday that it will present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the San Antonio Breast Cancer Symposium or SABCS from December 10-14, 2019.

These data include new results in HER2-positive breast cancer and studies of new molecules in hormone receptor-positive or HR-positive breast cancer. The study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer.

The company will present new data from a second interim overall survival analysis of the phase III APHINITY trial evaluating Perjeta (pertuzumab) and Herceptin (trastuzumab) plus chemotherapy (the Perjeta-based regimen), compared to Herceptin and chemotherapy, as an adjuvant treatment for HER2-positive early breast cancer or eBC.

Further, Roche will present data from the primary analysis of the phase III FeDeriCa study which evaluated a new investigational fixed-dose combination or FDC of Perjeta and Herceptin administered as a single subcutaneous formulation in combination with intravenous chemotherapy.

Data will also be presented from studies in HR-positive breast cancer, including findings from early studies investigating Roche's pipeline molecules GDC-9545, a selective oestrogen receptor degrader, and GDC-0077, a selective PI3Ka inhibitor.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3...
Follow RTT
>